The Protective Effect of Azelnidipine for the Prevention of Heart Fibrosis Occurrence on Balb/c Mice with Iron Overload

Authors

  • Hadi Sarosa Diponegoro University Postgraduate Program of Medical Sciences, Semarang, Indonesia & Departement of Physiology, Medical Faculty of Sultan Agung Islamic University Semarang, Indonesia
  • Udin Bahrudin Department of Cardiology and Vascular Medicine, Diponegoro University Faculty of Medicine, Semarang, Indonesia
  • Ag Soemantri Department of Pediatric, Diponegoro University Faculty of Medicine, Semarang, Indonesia
  • Siti Fatimah Muis Department of Nutrition, Diponegoro University Faculty of Medicine, Semarang, Indonesia
  • Nur Arfian Departement of Anatomy, Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada Yogyakarta, Indonesia
  • Ichiro Hisatome Division of Regenerative Medicine, Tottori University Graduate School of Medical Science, Yonago, Japan

DOI:

https://doi.org/10.3329/bjms.v19i2.44999

Keywords:

Azelnidipine; iron overload; expression of collagen; myocardium fibrosis

Abstract

Background: Iron overload can cause DNA oxidation which increase TGF β1, type 1 fibrilarprotein and myocardium fibrosis. Myocardium fibrosis is the main cause of death on the state of iron overload. The iron influx towards the cell during iron overload is still unknown, some research suggested LTCC acts as iron influx. This research aims to investigate the role of azelnidipine as type L calcium channel blocker, lowering TGF β1, collagen and myocardium fibrosis.

Method: The research subjects consisted of 25 male Balb-C mice(8 weeks, 30-40mg) divided into 5 groups. Group 1 (NaCl+S) 0,3 cc Na Cl 0,9% (I.P) and drug solvent (Aquabidest, CMC and Nipagin) orally. Group 2Fe+S) 0.3 cc 1,5 mg Fe+sucrose (Venofer®) (I.P) and drug solvent (Aquabidest, CMC and Nipagin) orally. Group 3 (Fe+Dfx) 1,5 mg Fe+sucrose (Venofer®) (I.P) and deferasirox 20 mg/kg body weight/day orally, group 4 (Fe+Azl) 1,5 mg Fe+sucrose (Venofer®) (I.P) and azelnidipine 14 mg/day orally and group 5 (Fe+Dfx-Azl) 1,5 mg Fe+sucrose (Venofer®) (I.P) and mixture of deferasirox 20 mg/kg body weight/day and azelnidipine 14 mg/day orally. Fe-sucorse was diluted with NaCl 0.9 %. Intraperitoneal injection were administered intermittently for 60 days of treatment.

Result: The highest Expression of TGF β, collagen I and fibrosis area fractions are in group Fe+S. The result of Post Hoc test between 2 treatment groups indicated that there were no difference in TGF β expression between groups NaCl+S with Fe+Dfx (P>0.05) , Fe+Dzl (P>0.05). There are no significant in collagen expression between groups NaCl+S with Fe+Dfx (P > 0.05) ,Fe+Dzl (P>0.05).

Conclusion: Azelnidipine, LTCC have roles on the influx of iron into the myocardium, lowering TGF β, collagen Iexpressionsand myocardium fibrosis.

Bangladesh Journal of Medical Science Vol.19(2) 2020 p.223-228

Downloads

Download data is not yet available.
Abstract
36
PDF
38

Downloads

Published

2020-01-16

How to Cite

Sarosa, H., Bahrudin, U., Soemantri, A., Muis, S. F., Arfian, N., & Hisatome, I. (2020). The Protective Effect of Azelnidipine for the Prevention of Heart Fibrosis Occurrence on Balb/c Mice with Iron Overload. Bangladesh Journal of Medical Science, 19(2), 223–228. https://doi.org/10.3329/bjms.v19i2.44999

Issue

Vol. 19 No. 2 (2020)

Section

Original Articles

License

Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:

  1. Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.

  2. Creative Commons Licence
    Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.